SHANGHAI, 24. März 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) gab bekannt, dass die Europäische Arzneimittel-Agentur (EMA) den Antrag für seinen selbst entwickelten Anti-PD-1 mAb HANSIZHUANG (Serplulimab) in Kombination mit einer Chemotherapie (Carboplatin und Etoposid)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.